Abstract
Immunotherapies that interfere with host defense cell mechanisms, enhance immune responses, reduce exacerbated inflammation, or balance host reactions on the site of pathology hold enormous promise for selective and symptomatic treatment of TB. Although we foresee a bright future for immunotherapy, this newly emerging treatment option should not be misinterpreted as an exclusive alternative, but rather it should be envisaged as a synergistic addition to canonical chemotherapy of TB.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
